Aktie A2P9Z1 ODYSSEY GROUP INTERNATIONAL, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Odyssey Group International, Inc. Other OTC

Aktien

A2P9Z1

US67612C1027

ODYY

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Odyssey Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023
Odyssey Health, Inc. Reports Earnings Results for the Full Year Ended July 31, 2023
Odyssey Health, Inc. Announces the Resignation of John Gandolfo as Director
Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate
Oragenics, Inc. entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.
Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS
AM Best Upgrades Credit Ratings of Odyssey Group Holdings, Inc.'s Members
Odyssey Health, Inc. executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.
Odyssey Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023
ODYSSEY HEALTH, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)
Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment
ODYSSEY HEALTH, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023
Odyssey Health, Inc. Forms Community-Based Partnership with David R. Metcalf Foundation for Military Concussion Research
ODYSSEY HEALTH, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
Odyssey Health, Inc. Appoints Jeffrey Conroy as Director
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2P9Z1 Aktie
  4. A2P9Z1 Aktie
  5. Nachrichten Odyssey Group International, Inc.
  6. Andere Sprachen